01931nas a2200253   4500000000100000008004100001260001200042653004700054653002700101100001200128700001200140700001200152700001200164700001500176700001500191700001300206700001300219245007400232856009900306300001300405490000700418520123800425022001401663       2020                            d  c07/202010aPost-kala-azar dermal leishmaniasis (PKDL)10aElimination programmes1 aGedda M1 aSingh B1 aKumar D1 aSingh A1 aMadhukar P1 aUpadhyay S1 aSingh OP1 aSundar S00aPost kala-azar dermal leishmaniasis: A threat to elimination program.  uhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0008221&type=printable  ae00082210 v143 a<p>Leishmaniasis remains a public health concern around the world that primarily affects poor folks of the developing world spanning across 98 countries with mortality of 0.2 million to 0.4 million annually. Post kala-azar dermal leishmaniasis (PKDL) is the late skin manifestation of visceral leishmaniasis (VL). It has been reported that about 2.5% to 20% of patients recovered from VL develop PKDL having stilted macular or nodular lesions with parasites. In the Indian subcontinent (ISC), it manifests a few months after recovery from VL, though in Africa it can occur simultaneously with VL or a little later. New cases of PKDL are also observed without prior VL in the ISC. These individuals with PKDL represent an important but largely neglected reservoir of infection that perpetuates anthroponotic Leishmania donovani transmission in the ISC and can jeopardize the VL elimination program as these cases can infect the sand flies and spread the endemic. Therefore, it becomes imperative to eradicate PKDL as a part of the VL elimination program. With the limited treatment options besides little knowledge on PKDL, this review stands out in focusing on different aspects that should be dealt for sustained VL elimination.</p>  a1935-2735